Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Arthritis, Rheumatoid × baricitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Skin Diseases, Papulosquamous 1 Skin Diseases 1 Sarcoma, Synovial 1 Sarcoma 1 Psoriasis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Plaque, Amyloid 1 Myelodysplastic Syndromes 1 Lymphoma, Follicular 1 Lymphoma 1 Liposarcoma, Myxoid 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Graft vs Host Disease 1 Chondrosarcoma 1 Bronchiolitis Obliterans Syndrome 1 Arthritis, Rheumatoid 1 Adenoma, Liver Cell 1

Interventions

Etanercept 16 Adalimumab 16 Methotrexate 10 Infliximab 8 tocilizumab 7 golimumab 6 Rituximab 6 tofacitinib 5 Abatacept 5 Tumor Necrosis Factor Inhibitors 4 Certolizumab Pegol 4 olokizumab 3 Saline Solution 2 RC-18 2 Nivolumab 2 Leflunomide 2 Antirheumatic Agents 2 veltuzumab 1 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 entecavir 1 baricitinib 1 andecaliximab 1 Vitamin D 1 Vaccines 1 Syringes 1 Surveys and Questionnaires 1 Sulfasalazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01721044 2019-09-18

RA-BEACON

Eli Lilly and Company

Phase 3 Completed

527 enrolled 37 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡